Disease · MONDO_0021211

brain neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. brain neoplasm. Diseases, record MONDO_0021211. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021211

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: brain neoplasm; Open Targets
Open Targets ID: MONDO_0021211; Open Targets
Other names: Brain Tumor, Recurrent, Brain Tumors, Brain Tumors, Recurrent, INTRACRANIAL NEOPL, Intracranial Neoplasm, Intracranial Neoplasms, NEOPL BRAIN, NEOPL INTRACRANIAL, Neoplasm, Brain, Neoplasm, Intracranial, Neoplasms, Brain, Neoplasms, Intracranial, PRIMARY BRAIN NEOPL, Recurrent Brain Tumor, Recurrent Brain Tumors, Tumor, Brain, Tumors, Brain, brain neoplasm (disease), brain neoplasms, brain tumor, brain tumour, neoplasm of brain, neoplasm of the brain, tumor of brain, tumor of the Brain, tumour of brain, tumour of the Brain; Open Targets
NCI Thesaurus: C2907; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 96 drugs, from DailyMed; Open Targets

Drugs96

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LOMUSTINE	CHEMBL514	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MANNITOL	CHEMBL689	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METHYLPHENIDATE	CHEMBL796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NOREPINEPHRINE	CHEMBL1437	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 96

See all 96 drugs

Targets190

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	7	Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 190

See all 190 targets

Trials88

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00271609	Bevacizumab for Recurrent Malignant Glioma	Phase 2	88	2012-06-08	Recurrent High-Grade Gliomas, Malignant Gliomas	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00050986	Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme	Phase 1/2	55	2010-09-16	Glioblastoma Multiforme	TEMOZOLOMIDE, TIPIFARNIB	Its record names the disease	ClinicalTrials.gov
NCT00003458	Antineoplaston Therapy in Treating Children With Brain Tumors	Phase 2	34	2017-01-19	Childhood Brain Tumors	ANTINEOPLASTON A10	Its record names the disease	ClinicalTrials.gov
NCT00418691	Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning	Phase 3	34	2011-05-06	Brain Tumor	METHYLPHENIDATE, MODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT00763750	PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors	Phase 2	25	2013-12-16	Brain Tumor	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02193347	IDH1 Peptide Vaccine for Recurrent Grade II Glioma	Phase 1	24	2021-03-15	Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2	20	2023-04-27	Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor	TAZEMETOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00098865	Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma	Phase 2	15	2014-09-25	Central Nervous System Tumor, Pediatric, Neuroblastoma	TEMOZOLOMIDE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00452868	Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain	Early phase 1	14	2013-02-28	Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity	DONEPEZIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04497142	Effect of Perampanel on Peritumoral Hyperexcitability in HGG	Phase 1/2	12	2024-08-05	Glioma, Malignant, Surgery, Seizures	PERAMPANEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 88

See all 88 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): Number of Participants With Adverse Events	32 of 32	51 of 56	88	NCT00271609	Trial comparisons
Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): serious adverse events	11 of 32	24 of 56	88	NCT00271609	Trial comparisons
Perampanel + Electrocorticography vs Standard of Care + Electrocorticography: deaths from any cause	0 of 8	0 of 4	12	NCT04497142	Trial comparisons
Perampanel + Electrocorticography vs Standard of Care + Electrocorticography: serious adverse events	0 of 8	0 of 4	12	NCT04497142	Trial comparisons
Perampanel + Electrocorticography vs Standard of Care + Electrocorticography: Seizure-freedom	1 of 7	2 of 4	11	NCT04497142	Trial comparisons
Arm A (MRI-guided Laser Ablation) vs Arm B (MRI-guided Laser Ablation, Doxorubicin, Etoposide): deaths from any cause	0 of 5	0 of 1	6	NCT02372409	Trial comparisons
Arm A (MRI-guided Laser Ablation) vs Arm B (MRI-guided Laser Ablation, Doxorubicin, Etoposide): serious adverse events	0 of 5	0 of 1	6	NCT02372409	Trial comparisons
Arm 1 vs Arm 2: deaths from any cause	2 of 3	1 of 2	5	NCT03330197	Trial comparisons
Arm 1 vs Arm 2: serious adverse events	1 of 3	1 of 2	5	NCT03330197	Trial comparisons

Papers from its trials36

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36682527	RESULT	1	PubMed
33092063	RESULT	1	PubMed
29864216	RESULT	1	PubMed
28114177	RESULT	1	PubMed
25313193	RESULT	1	PubMed
21865400	RESULT	1	PubMed
21109143	RESULT	1	PubMed
20460632	RESULT	1	PubMed
20049936	RESULT	1	PubMed
19065567	RESULT	1	PubMed

1 to 10 of 36

See all 36 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021211

GET https://conductscience.org/api/diseases/v1/MONDO_0021211/drugs?page=2

API reference For AI assistants